Editorial Indian Pediatrics 2008; 45:452-453 |
|
Pitfalls in Investigating for Diabetes Insipidus |
|
Factors such as the pattern of fluid intake, baseline biochemistry, the response to desmopressin and a period of observation in hospital may all prove to be extremely useful parameters when assessing a child with polydipsia. Hence, there is much more to the assessment of these children than deprivation testing alone. In our center, we have ‘hijacked’ the language of our local genetics team and talk about some children ‘growing’ into a diagnosis. This makes the point that one test does not necessarily provide an answer and information may need to be gathered over a period of time before a diagnosis is reached. Bajpai and colleagues highlight a number of important points in their article about the presentation of young people with idiopathic and organic cranial diabetes insipidus (CDI)(1). Perhaps the key lesson is the central role of intracranial imaging in the investigation of patients with CDI. The authors discuss the importance of considering repeat intracranial imaging in children with what might appear to be ‘idiopathic’ cranial DI on the first set of images. It is well known that children with CDI secondary to an underlying germinoma may have no evidence of the malignant process on MR scanning until months or even years later(2). The more profound phenotype in those patients with CDI secondary to organic pathology will partly reflect the impact ofthe disease process on anterior pituitary function. Unfortunately, the two groups of children (idiopathic and organic) in Bajpai and colleagues study do not segregate neatly into distinct groups in terms of age or height. This reinforces the importance of ongoing vigilance as well as the need to re-image all patients with supposedly idiopathic DI at a later date. Although many familial cases of cranial DI do not result in a profound phenotype in early life, presentation in infancy with failure to thrive is well recognized(3). Children can, therefore, grow poorly in the absence of anterior pituitary disease. Furthermore, growth can be surprisingly well preserved in patients with central nervous system disease as part of the phenomenon of ‘growth without growth hormone’(4). Patients with ‘idiopathic’ CDI were also relatively short in Bajpai and colleagues study (–1.0 SDS) which could be interpreted as meaning that they may not have ‘idiopathic’ CDI after all. The proportion of patients with idiopathic disease in case series like this will tend to fall as our understanding of diseases and disease evolution evolves. Hence, some of the idiopathic groups in this study may in fact have underlying autoimmune destruction(5) or vascular impairment(6). A pediatrician should remember that there are few rules or tests that have 100% sensitivity and specificity for diagnosing DI in a short child. Furthermore, what is simply ‘idiopathic’ CDI in one year may not prove to be idiopathic the next. Funding: None. Competing interests: None stated. Tim Cheetham,
|